Ulcerative Colitis

Timothy L. Zisman*, Stephen B. Hanauer

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Inflammatory bowel disease encompasses a spectrum between ulcerative colitis and Crohn's disease. Ulcerative colitis is manifest by diffuse, continuous and superficial inflammation that begins in the rectum and extends proximally to a variable extent in individual patients. In approximately 15% of patients with inflammatory bowel disease confined to the colon the pattern of inflammation is not distinguishable, necessitating the term indeterminate colitis or IBD-U (unclassified). Features that are helpful to discriminate between ulcerative colitis and Crohn's disease include: family history, smoking history, presence of perianal manifestations, aphthous ulcerations, strictures and fistulae. Therapeutic approaches are aimed at induction and maintenance of clinical remissions. Inductive agents include aminosalicylates, corticosteroids, cyclosporine and monoclonal antibodies targeting tumor necrosis factor (TNF). Maintenance therapies include aminosalicylates, thiopurines, or anti-TNF agents. Colectomy is an option for refractory disease.

Original languageEnglish (US)
Title of host publicationPractical Gastroenterology and Hepatology
Subtitle of host publicationSmall and Large Intestine and Pancreas
PublisherWiley Blackwell
Pages304-311
Number of pages8
ISBN (Print)9781405182744
DOIs
StatePublished - Aug 31 2010

Keywords

  • 5-aminosalicylic acid
  • Colitis
  • Crohn disease
  • Cyclosporine
  • Inflammatory bowel disease
  • Methotrexate
  • Thiopurine
  • Tumor necrosis factor
  • Ulcerative colitis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Ulcerative Colitis'. Together they form a unique fingerprint.

Cite this